KromaTiD Inc., a Fort Collins-based biotech company, has joined the National Institute of Standards and Technology Genome Editing Consortium, a newly launched public/private partnership.
The consortium supports the emerging gene-editing market and regulatory-agency needs for standardized measurements of gene edits, editing byproducts and the risks of using genome-editing technologies in research, commercial and therapeutic products.
KromaTiD’s dGH technology is a commercial structural genomic platform that detects random, low-frequency and complex structural variations in batches of gene-edited cells. By directly reading the genomic structure of individual edited cells, dGH provides definitive, quantitative data for on- and off-target structural variation.
Through a cooperative research and development agreement, KromaTiD will transfer dGH technology to laboratories at NIST and other consortium members.
This article was originally found in BizWest.